May 22, 2017
Today we will be talking about the use of naltrexone for the treatment of opioid use disorder therapy. Naltrexone is an opioid blocker, or antagonist, that has limited prevalence of use compared with buprenorphine, a partial agonist, and methadone, a long-acting agonist. Joining us for this conversation is Dr. Adam Bisaga, an academic psychiatrist, educator and clinician. He is a Professor of Psychiatry at the Columbia University Medical Center, and a Research Scientist at the New York State Psychiatric Institute. He was a recipient of a Career Development Award and a Principal Investigator on grants funded by the National Institute of Drug Abuse. His research interests include development of human laboratory and clinical trial models for testing medications to treat substance use disorders, including trials to improve effectiveness of antagonist-based treatment of opioid use disorder. Dr. Bisaga publishes and lectures in the area of addiction research and he is a member of the editorial board of the journal Addiction.